These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 36553481

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S, Bai H, Fei S, Miao B.
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [Abstract] [Full Text] [Related]

  • 3. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y, Gong P, Su L, Zhang M.
    Sci Rep; 2023 Nov 27; 13(1):20870. PubMed ID: 38012210
    [Abstract] [Full Text] [Related]

  • 4. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
    Song Z, Su M, Li X, Xie J, Han F, Yao J.
    BMC Gastroenterol; 2023 Dec 09; 23(1):432. PubMed ID: 38066437
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y, Zhang Q, Zhang H, Kong F.
    Funct Integr Genomics; 2023 Jan 14; 23(1):38. PubMed ID: 36640225
    [Abstract] [Full Text] [Related]

  • 11. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X, Ye Z, Xiao G, He T.
    Comput Biol Med; 2023 Jun 14; 159():106905. PubMed ID: 37060773
    [Abstract] [Full Text] [Related]

  • 12. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
    Zhang N, Yu X, Sun H, Zhao Y, Wu J, Liu G.
    Medicine (Baltimore); 2023 Oct 20; 102(42):e35167. PubMed ID: 37861553
    [Abstract] [Full Text] [Related]

  • 13. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C, Li F, Gu Z, Yang Y, Qi Y.
    Front Pharmacol; 2023 Oct 20; 14():1146840. PubMed ID: 37670938
    [Abstract] [Full Text] [Related]

  • 14. The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.
    He C, Zhu X, Kong F, Zhang X, Chai X, Zou C, Zhao D.
    Biomed Res Int; 2022 Oct 20; 2022():2747799. PubMed ID: 35711526
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L, Xiao K, Dong Z, Meng T, Cheng X, Xu Y.
    J Cancer Res Clin Oncol; 2023 Sep 20; 149(12):10543-10559. PubMed ID: 37291405
    [Abstract] [Full Text] [Related]

  • 18. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C, Zhang C, Wang H, Li K, Zhao L.
    BMC Cancer; 2021 Dec 07; 21(1):1312. PubMed ID: 34876056
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C, Wu S, Lai L, Liu J, Guo Z, Ye Z, Chen X.
    BMC Bioinformatics; 2023 Jan 03; 24(1):4. PubMed ID: 36597032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.